Previous studies reported differences in the immune microenvironment between the primary CRC and liver metastasis, and more CD33+ cells and CD8+ cells, but not CD8+ T cells in liver metastases; these results suggested that increased numbers of immunosuppressing cells in the liver may contribute to the poor response to immunotherapy [9]. Here, CD33 is linked to colorectal carcinoma.